



SanoGene Therapeutics Inc.
Chicago, Illinois
Contact: Caralynn V. Nowinski, M.D.,
Co-Founder & Interim CEO
Tel: (312) 927-3570
cnowinski@sanogene.com

SanoGene Exclusively Licenses Key Intellectual Property and Forms Strategic Partnership with Cato Research Ltd.

CHICAGO, ILLINOIS, May 14, 2008—SanoGene Therapeutics Inc. (www.sanogene.com), a privately held, early stage biotechnology company developing cancer therapeutics, announced today that it has obtained exclusive rights from the University of Illinois to worldwide patent applications covering the methods and compositions of multi-targeted short interfering RNA (siRNA) constructs used to inhibit tumor formation and regress pre-formed tumors.

The company also announced today a strategic equity investment by Cato BioVentures (www.catobioventures.com) and partnership with its global contract research and development organization Cato Research Ltd. (www.cato.com). The investment and partnership will help support continued development of SanoGene's lead drug candidate for cancer treatment.

SanoGene's lead candidate, SG-1311, has demonstrated efficacy in animal models of glioblastoma multiforme, the most common and deadliest form of primary brain cancer. Patients with this form of cancer rarely survive beyond 12 months from diagnosis. SanoGene's proprietary constructs simultaneously block the activity of multiple cancer-promoting genes to potentially stop tumor progression, block healthy tissue invasion, and promote cancer cell death.

"We are proud to have the opportunity to advance this core technology out of the research lab and into the clinic," said Caralynn Nowinski, M.D., President and Acting CEO of SanoGene. "The support and expertise of the Cato team will enable us to take a substantial step forward in this process as we drive toward patient trials."

"Cato BioVentures has a long track record of supporting early-stage biotech companies and looks forward to a long and successful relationship with SanoGene as we assist the company in achieving important near-term milestones by leveraging the experience of Cato Research," said Joel Eisner, Ph.D., Associate Principal of Cato BioVentures.

Last month SanoGene was awarded a grant from the Chicago Community Ventures' Challenge Grant Program, funded by the Illinois Department of Commerce and Economic Opportunity. The company was previously recognized as the winner of the 2007 Chicago City Treasurer's Small Business Plan Competition and the DCEO-sponsored University Business Plan Competition at the 2006 Midwest Venture Summit.

About SanoGene

SanoGene Therapeutics Inc. is an early stage biotechnology company, utilizing innovative RNAi-based technologies to develop biopharmaceutical products for deadly cancers. The Company's platform technology combines the capabilities of multiple therapeutics into one deliverable product with synergistic effects. This proprietary multi-targeted approach is employed in the development of a pipeline of drug candidates with the potential to treat multiple cancers. Founded at the University of Illinois College of Medicine, SanoGene brings together scientific and managerial talent, proprietary technology and a scalable business model to deliver the next generation of cancer treatment.

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley.

CONTACT: Caralynn Nowinski, M.D., cnowinski@sanogene.com or 312-927-3570
Joel Eisner, Ph.D., [jeisner @cato.com](mailto:jeisner@cato.com) or 919-361-2286

###